HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use XELJANZ/XELJANZ XR/XELJANZ Oral Solution safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR/XELJANZ Oral Solution.
XELJANZ® (tofacitinib) tablets, for oral use
XELJANZ® XR (tofacitinib) extended-release tablets, for oral use
XELJANZ® (tofacitinib) Oral Solution
Initial U.S. Approval: 2012
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.